Da-Qiang Li[Author] - Search Results

Year	Number of Results
2004	6
2006	3
2007	2
2008	2
2009	3
2010	7
2011	7
2012	7
2013	7
2014	3
2015	2
2016	2
2017	4
2018	5
2019	8
2020	10
2021	5
2022	12
2023	9
2024	2

1

Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.

Yang F, Xiao Y, Ding JH, Jin X, Ma D, Li DQ, Shi JX, Huang W, Wang YP, Jiang YZ, Shao ZM. Yang F, et al. Among authors: li dq. Cell Metab. 2023 Jan 3;35(1):84-100.e8. doi: 10.1016/j.cmet.2022.09.021. Epub 2022 Oct 17. Cell Metab. 2023. PMID: 36257316 Free article.

2

Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.

Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng Y, Li X, Zhang C, Hu P, Zhang J, Hua Q, Zhang J, Hou W, Ren L, Bao D, Li B, Yang J, Yao L, Zuo WJ, Zhao S, Gong Y, Ren YX, Zhao YX, Yang YS, Niu Z, Cao ZG, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li DQ, Wang P, Shi L, Huang W, Shao ZM. Jiang YZ, et al. Among authors: li dq. Cancer Cell. 2019 Mar 18;35(3):428-440.e5. doi: 10.1016/j.ccell.2019.02.001. Epub 2019 Mar 7. Cancer Cell. 2019. PMID: 30853353 Free article.

3

The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer.

Wang H, Rong X, Zhao G, Zhou Y, Xiao Y, Ma D, Jin X, Wu Y, Yan Y, Yang H, Zhou Y, Qian M, Niu C, Hu X, Li DQ, Liu Q, Wen Y, Jiang YZ, Zhao C, Shao ZM. Wang H, et al. Among authors: li dq. Cell Metab. 2022 Apr 5;34(4):581-594.e8. doi: 10.1016/j.cmet.2022.02.010. Epub 2022 Mar 11. Cell Metab. 2022. PMID: 35278352 Free article.

4

Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets.

Gong Y, Ji P, Yang YS, Xie S, Yu TJ, Xiao Y, Jin ML, Ma D, Guo LW, Pei YC, Chai WJ, Li DQ, Bai F, Bertucci F, Hu X, Jiang YZ, Shao ZM. Gong Y, et al. Among authors: li dq. Cell Metab. 2021 Jan 5;33(1):51-64.e9. doi: 10.1016/j.cmet.2020.10.012. Epub 2020 Nov 11. Cell Metab. 2021. PMID: 33181091 Free article.

5

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.

Xiao Y, Ma D, Yang YS, Yang F, Ding JH, Gong Y, Jiang L, Ge LP, Wu SY, Yu Q, Zhang Q, Bertucci F, Sun Q, Hu X, Li DQ, Shao ZM, Jiang YZ. Xiao Y, et al. Among authors: li dq. Cell Res. 2022 May;32(5):477-490. doi: 10.1038/s41422-022-00614-0. Epub 2022 Feb 1. Cell Res. 2022. PMID: 35105939 Free PMC article.

6

Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.

Liao L, Zhang YL, Deng L, Chen C, Ma XY, Andriani L, Yang SY, Hu SY, Zhang FL, Shao ZM, Li DQ. Liao L, et al. Among authors: li dq. Cancer Res. 2023 Feb 3;83(3):471-484. doi: 10.1158/0008-5472.CAN-22-2709. Cancer Res. 2023. PMID: 36484700 Free PMC article.

7

O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression.

Liu YY, Liu HY, Yu TJ, Lu Q, Zhang FL, Liu GY, Shao ZM, Li DQ. Liu YY, et al. Among authors: li dq. Cell Death Differ. 2022 Apr;29(4):861-873. doi: 10.1038/s41418-021-00901-0. Epub 2022 Jan 1. Cell Death Differ. 2022. PMID: 34974534 Free PMC article.

8

TOLLIP-mediated autophagic degradation pathway links the VCP-TMEM63A-DERL1 signaling axis to triple-negative breast cancer progression.

Zhang TM, Liao L, Yang SY, Huang MY, Zhang YL, Deng L, Hu SY, Yang F, Zhang FL, Shao ZM, Li DQ. Zhang TM, et al. Among authors: li dq. Autophagy. 2023 Mar;19(3):805-821. doi: 10.1080/15548627.2022.2103992. Epub 2022 Aug 3. Autophagy. 2023. PMID: 35920704 Free PMC article.

9

Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer.

Zhang FL, Yang SY, Liao L, Zhang TM, Zhang YL, Hu SY, Deng L, Huang MY, Andriani L, Ma XY, Shao ZM, Li DQ. Zhang FL, et al. Among authors: li dq. Theranostics. 2023 Jan 22;13(3):973-990. doi: 10.7150/thno.79688. eCollection 2023. Theranostics. 2023. PMID: 36793866 Free PMC article.

10

Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer.

Liu HY, Liu YY, Yang F, Zhang L, Zhang FL, Hu X, Shao ZM, Li DQ. Liu HY, et al. Among authors: li dq. Nucleic Acids Res. 2020 Apr 17;48(7):3638-3656. doi: 10.1093/nar/gkaa130. Nucleic Acids Res. 2020. PMID: 32112098 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

95 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Results by year